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Symposium 4: Hot topics in parenteral nutrition
Current evidence and ongoing trials on the use of glutamine in
critically-ill patients and patients undergoing surgery
Alison Avenell
Health Services Research Unit, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK
The amino acid glutamine has numerous important roles including particularly antioxidant
defence, immune function, the inflammatory response, acid–base balance and N economy. The
present systematic review of randomised controlled trials of nutrition support with glutamine
up to August 2008 has found that parenteral glutamine in critical illness is associated with a
non-significant reduction in mortality (risk ratio 0.71 (95% CI 0.49, 1.03)) and may reduce
infections. However, poor study quality and the possibility of publication bias mean that these
results should be interpreted with caution. There is no evidence to suggest that glutamine is
harmful in terms of organ failure and parenteral glutamine may reduce the development of
organ failure.
Glutamine: Systematic review: Critical illness
There are many potential mechanisms by which supple-
mentation with the amino acid glutamine could prove
beneficial in critical illness. Plasma glutamine levels fall in
patients with critical illness and glutamine is released from
muscle to be used by rapidly-dividing cells (such as the
gut and immune system) and for renal acid–base homeo-
stasis(1). The fall in glutamine levels may suggest that
glutamine becomes a ‘conditionally essential’ amino acid
in critical illness. Glutamine supplementation improves N
balance in parenteral nutrition support(2). Glutamine is
particularly important as a precursor of glutathione and
thus in antioxidant defence.
Glutamine also plays a role in intracellular signalling,
enhances heat-shock protein expression(3), prevents apop-
tosis in injury and attenuates hyperinflammation(1). There
is some evidence to suggest that glutamine may reduce gut
injury and inflammation in critical illness, thus influencing
bacterial translocation across the gut wall(4). Glutamine
may also improve insulin sensitivity in critical illness(5).
With the ability now to provide glutamine in parenteral
nutrition, as well as additional enteral supplements, ran-
domised controlled trials have evaluated whether gluta-
mine provides clinical benefits.
Guidelines for the use of glutamine in critical illness
have recommended enteral glutamine for patients with
burns or trauma and parenteral glutamine where parenteral
nutrition is required(6). However, not all guidelines for
critical illness have supported the use of parenteral gluta-
mine for all patients requiring parenteral nutrition and the
quality of trials has been considered poor for guideline
recommendations(7).
It has been shown that surgery causes some cytokine
activation and some depression of cellular defences(8), but
the systemic inflammatory response of critical illness is
best represented by hyperinflammation and marked cellular
immune dysfunction at the same time. Thus, responses to
glutamine supplementation may differ between patients
undergoing surgery and critically-ill patients. The present
systematic review examines the use of glutamine parent-
erally and enterally in critical illness and surgical groups of
patients separately.
Methods
A systematic review and meta-analyses of randomised
controlled trials were undertaken using a prespecified
Abbreviation: RR, risk ratio.
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protocol. Randomised controlled trials compared glutamine-
containing parenteral or enteral nutrition with control
feeding in adult patients undergoing surgery or with cri-
tical illness. It was assumed that regimens given to
intervention and control groups were isonitrogenous and
isoenergetic, but whether this assumption reflected practice
was not always clear from the reports. Randomised con-
trolled trials of immunonutrition, in which glutamine was
Study or subcategory  
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100·00 0·84
0·83, 3·56
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7·00
0·33
0·92
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0·49, 1·03
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0·06, 0·93
0·57, 1·49
0·30, 5·31
0·50, 2·08
0·50, 4·17
0·01, 3·70
0·90, 8·18
0·71, 1·54
0·39, 1·32
0·39, 1·32
0·07, 15·1
0·07, 15·1
0·66, 1·07
Not estimatable
Not estimatable
Not estimatable
0·1 0·2 0·5 1 2 5 10
Critical illness PN
Déchelotte et al.(15)
Estivariz et al.(16)
Fuentes-Orozco et al.(18)
Fuentes-Orozco et al.(17)
Goeters et al.(20)
Griffiths et al.(21)
Luo et al.(28)
Ockenga et al.(33)
Perez-Barcena et al.(36)
Sahin et al.(38)
Tjäder et al.(41)
Wischmeyer et al.(42)
Subtotal (95 % CI)
   Total events: 68 (treatment), 85 (control)
   Test for heterogeneity: χ2 13·4, df 10 (P=0·20), I2  25·5 %
   Test for overall effect: Z 1·81 (P=0·07)
Critical illness EN
Brantley & Pierce(12)
Conejero et al.(13)
Garrel et al.(19)
Hall et al.(22)
Houdijk et al.(23)
Jones et al.(25)
Kumar et al.(27)
McQuiggan et al.(29)
Schulman et al.(39)
Subtotal (95 % CI)
   Total events: 75 (treatment), 72 (control)
   Test for heterogeneity: χ2 9·52, df 7 (P=0·22), I2  26·5 %
   Test for overall effect: Z 0·24 (P=0·81)
Critical illness and surgical PN
Powell-Tuck et al.(37)
Subtotal (95 % CI)
   Total events: 14 (treatment), 20 (control)
   Test for heterogeneity:  not applicable
   Test for overall effect: Z 1·07 (P=0·29)
Surgical PN
Mertes et al.(30)
Oguz et al.(34)
Subtotal (95 % CI)
   Total events: 1 (treatment), 1 (control)
   Test for heterogeneity:  not applicable
   Test for overall effect: Z 0·00 (P=1·00)
Total (95 % CI)
   Total events: 158 (treatment), 178 (control)
   Test for heterogeneity: χ2 26·2, df 20 (P=0·16), I2  23·5 %
   Test for overall effect: Z 1·38 (P=0·17)
Favours treatment Favours control
Fig. 1. Meta-analysis of glutamine-supplemented parenteral (PN) or enteral (EN) nutrition in critical illness and surgery; risk ratios (RR)
for mortality. n, No. of patients affected in treatment or control group; N, total no. of patients in treatment or control group; ‹ ,!, values
extend beyond the range of the values shown.
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one of several nutrients, e.g. with arginine or n-3 fatty
acids, were not included.
Randomised controlled trials were identified by search-
ing three databases (MEDLINE, EMBASE, CINAHL),
hand searching four journals (Clinical Nutrition, Journal of
Parenteral and Enteral Nutrition, Intensive Care Medicine,
Critical Care Medicine) and from previous reviews,
including that by Novak et al.(9). Full published reports,
conference proceedings and abstracts provided data. There
were no language exclusions, but the review did not
0·1 0·2 0·5 1 2 5 10
Critical illness PN
de Beaux et al.(14) 
Déchelotte et al.(15)
Estivariz et al.(16)
Fuentes-Orozco et al.(18)
Fuentes-Orozco et al.(17)
Griffiths et al.(21)
Ockenga et al.(33)
Perez-Barcena et al.(36)
Sahin et al.(38)
Wischmeyer et al.(42)
Subtotal (95 % CI)
   Total events: 104 (treatment), 136 (control)
   Test for heterogeneity: χ2 12·9, df 9 (P=0·17), I2  30·4 %
   Test for overall effect: Z 2·24 (P=0·03)
Critical illness EN
Conejero et al.(13)
Garrel et al.(19)
Hall et al.(22)
Houdijk et al.(23)
Kumar et al.(27)
Schulman et al.(39)
Subtotal (95 % CI)
   Total events: 158 (treatment), 171 (control)
   Test for heterogeneity: χ2 7·98, df 5 (P=0·16), I2  37·3 %
   Test for overall effect: Z 0·98 (P=0·33)
Surgical PN
Jacobi et al.(24)
Klek et al.(26)
Neri et al.(31)
O'Riordain et al.(35)
Oguz et al.(34)
Spittler et al.(40)
Subtotal (95 % CI)
   Total events: 20 (treatment), 43 (control)
   Test for heterogeneity: χ2 1·05, df 5 (P=0·96), I2  0 %
   Test for overall effect: Z 3·45 (P=0·0006)
Total (95 % CI)
   Total events: 321 (treatment), 389 (control)
   Test for heterogeneity: χ2 34·2, df 23 (P=0·06), I2  32·7 %
   Test for overall effect: Z 2·96 (P=0·003)
Favours treatment Favours control
Critical illness and surgical
Powell-Tuck et al.(37)
Subtotal (95 % CI)
   Total events: 37 (treatment), 38 (control)
   Test for heterogeneity:  not applicable
   Test for overall effect: Z 0·02 (P=0·99)
Surgical EN
Nitta et al.(32)
Subtotal (95 % CI)
   Total events: 2 (treatment), 1 (control)
   Test for heterogeneity:  not applicable
   Test for overall effect: Z 0·74 (P=0·46)
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Fig. 2. Meta-analysis of glutamine-supplemented parenteral (PN) or enteral (EN) nutrition in critical illness and surgery; risk ratios (RR)
for participants with infection. n, No. of patients affected in treatment or control group; N, total no. of patients in treatment or control
group; ‹ , !, values extend beyond the range of the values shown.
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include trials from China, because of continuing concerns
over the authenticity of randomised trial designs from
China(10). The last date for the search was August 2008.
Data on deaths, participants with infection and par-
ticipants with organ failure are presented. A conservative
method of data handling was used. Outcomes were taken
from the last available time of follow-up, with a random
effects model for meta-analysis (except in the case of the
data used in the funnel plot). Data are presented with all
participants randomised as the denominator. Post hoc
subgroup analyses examined mortality in critical illness for
glutamine dose calculated as dose/kg body weight · period
(d) of ‡4.2 g/kg body weight compared with <4.2 g/kg
body weight, and for patients with acute pancreatitis.
Heterogeneity amongst trials was assessed by the I2
statistic(11), where ‡50% was taken as indicating sig-
nificant heterogeneity. Publication bias was examined by
funnel plot analysis. Meta-analyses were undertaken using
Review Manager version 4.2.7 software (Cochrane Colla-
boration, Oxford, UK). Risk ratios (RR), OR and 95% CI
are reported.
Results
Data are presented from thirty-one randomised controlled
trials that provided data(12–42). Twenty-two trials were
identified in patients with critical illness (burns, two trials;
mixed intensive care unit population, nine trials; patients
with trauma, three trials; patients with pancreatitis, four
trials; patients with surgical complications, four trials).
Eight trials were in patients undergoing elective gastro-
intestinal surgery, for whom parenteral nutrition support
post-operatively would not normally be provided. One trial
Parenteral nutrition
Estivariz et al.(16)
Fuentes-Orozco et al.(18)
Fuentes-Orozco et al.(17)
Goeters et al.(20)
Griffiths et al.(21)
Sahin et al.(38)
Wischmeyer et al.(42)
Subtotal (95 % CI)
   Total events: 34 (treatment), 61 (control)
   Test for heterogeneity: χ2 3·40, df 6 (P=0·76), I2  0 %
   Test for overall effect: Z 2·87 (P=0·004)
Enteral nutrition
Conejero et al.(13)
Garrel et al.(19)
Hall et al.(22)
Subtotal (95 % CI)
   Total events: 31 (treatment), 26 (control)
   Test for heterogeneity: χ2 1·09, df 2 (P=0·58), I2  0 %
   Test for overall effect: Z 0·54 (P=0·59)
Total (95 % CI)
   Total events: 65 (treatment), 87 (control)
   Test for heterogeneity: χ2 8·86, df 9 (P=0·45), I2  0 %
   Test for overall effect: Z 2·01 (P=0·04)
0
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15
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22
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15
220
2
2
5
20
22
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31
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42
20
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219
0·19
0·47
0·40
0·65
0·68
0·22
1·07
0·60
0·01, 3·88
0·05, 4·70
0·09, 1·85
0·35, 1·20
0·41, 1·12
0·05, 0·90
0·07, 15·6
0·42, 0·85
12
0
19
47
19
179
245
37
22
184
243
6
1
19
1·57
0·38
1·03
1·15
0·65, 3·80
0·02, 8·89
0·56, 1·88
0·70, 1·87
465 462
0·91
1·55
3·51
21·54
33·10
4·18
1·14
65·93
10·59
0·83
22·66
34·07
100·00 0·75 0·56, 0·99
0·1 0·2 0·5 1 2 5 10
Favours treatment Favours control
Study or subcategory  
Treatment Control
RR (random) and 95 % CI RR (random)
Weight
(%) 95 % CIn Nn N
Fig. 4. Meta-analysis of glutamine-supplemented parenteral or enteral nutrition in critical illness and surgery; risk ratios (RR) for
participants developing organ failure (other than requiring ventilation. n, No. of patients affected in treatment or control group; N, total
no. of patients in treatment or control group; ‹ , !, values extend beyond the range of the values shown.
0·0
0·4
0·8
1·2
1·6
0·1 0·2 0·5 1 2 5 10
SE
(lo
g R
R)
RR (fixed)
Fig. 3. Funnel plot examination for publication bias from infection
data shown in Fig. 2. SE (log RR), SE of the log of the risk ratio; RR
(fixed), risk ratio (fixed effect model).
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evaluated glutamine-containing parenteral nutrition in a
mixed hospital population cared for by the nutrition
team(37).
Trial quality, as reported, was often limited, particularly
in terms of reporting concealment of randomisation,
intention-to-treat analysis and blinding of outcome assess-
ment (although this factor is not likely to be a problem for
reporting of deaths).
Mortality
Parenteral glutamine in critical illness was associated with
a non-significant reduction in mortality (RR 0.71 (95% CI
0.49, 1.03); P = 0.07; Fig. 1). For enteral glutamine in
critical illness the RR was 1.05 (95% CI 0.71, 1.54;
P = 0.81). Two surgical trials reported mortality and one
trial reported for a mixed hospital population, in neither
case was there a significant reduction. Overall, if all
population groups are combined the RR for mortality was
0.84 (95% CI 0.66, 1.07; P = 0.17). Thus, there was a
trend for a beneficial effect, most clearly for parenteral
glutamine in critical illness.
Participants with infection
For enteral glutamine in critical illness the RR was 0.91
(95% CI 0.74, 1.10; P = 0.33; Fig. 2). Parenteral glutamine
in critical illness was associated with a significant reduc-
tion in infections (RR 0.78 (95% CI 0.63, 0.97); P = 0.03).
In patients following surgery who were given parenteral
nutrition containing glutamine, whether they required par-
enteral nutrition or not, there was a significant reduction in
participants with infection (RR 0.43 (95% CI 0.27, 0.69);
P<0.001). Overall, for all patient groups there was a sig-
nificant reduction in participants with infection (RR 0.81
(95% CI 0.70, 0.93); P = 0.003).
For the outcome of participants with infection, which
provided the most data, a funnel plot examining for sug-
gestion of publication bias was undertaken (Fig. 3). The
individual data points should be evenly distributed in an
inverted ‘V’ on either side of the vertical axis. The plot
shows fewer data points to the top right of the line, sug-
gesting that small trials with negative results, not in favour
of glutamine, were less likely to be published.
Participants with multi-organ or renal failure
Few trials reported multi-organ or renal failure. Combining
all parenteral glutamine trials there was a significant
reduction (RR 0.60 (95% CI 0.42, 0.85); P = 0.004;
Fig. 4), but not for enteral glutamine (RR 1.15 (95% CI
0.70, 1.87); P = 0.59). Overall, there was no suggestion
that glutamine was harmful in terms of multi-organ or
renal failure (RR 0.75 (95% CI 0.56, 0.99); P = 0.04).
0·1 0·2 0·5 1 2 5 10
Favours treatment Favours control
Study or subcategory  
Treatment Control
RR (random) and 95 % CI RR (random)
Weight
(%) 95 % CIn Nn N
Fuentes-Orozco et al.(17)
Ockenga et al.(33)
Sahin et al·(38)
Total (95 % CI)
   Total events: 4 (treatment), 12 (control)
   Test for heterogeneity: χ2 0·03, df 2 (P=0·98), I2  0 %
   Test for overall effect: Z 1·99 (P=0·05)
2
0
2
5
1
6
22
14
20
0·40
0·33
0·33
0·09, 1·85
0·01, 7·55
0·08, 1·46
22
14
20
56 56
43·19
10·38
46·42
100·00 0·36 0·13, 0·99
Fig. 5. Meta-analysis of glutamine-supplemented parenteral nutrition in pancreatitis; risk ratios (RR) for mortality. n, Number
affected in treatment or control group; N, total no. of patients in treatment or control group; ‹ , !, values extend beyond the
range of the values shown.
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Favours treatment Favours control
Study or subcategory  
Treatment Control
RR (random) and 95 % CI RR (random)
Weight
(%) 95 % CIn Nn N
de Beaux et al.(14)
Fuentes-Orozco et al.(17)
Ockenga et al.(33)
Sahin et al.(38)
Total (95 % CI)
   Total events: 9 (treatment), 21 (control)
   Test for heterogeneity: χ2 4·11, df 3 (P=0·25), I2  27·1 %
   Test for overall effect: Z 1·62 (P=0·10)
1
4
4
0
7
17
14
20
0
12
5
4
7
16
14
20
3·00
0·31
0·80
0·11
0·14, 63·2
0·13, 0·77
0·27, 2·37
0·01, 1·94
58 57
7·54
46·17
37·81
8·47
100·00 0·49 0·20, 1·16
Fig. 6. Meta-analysis of glutamine-supplemented parenteral nutrition in pancreatitis; risk ratios (RR) for participants
with infection. n, No. of patients affected in treatment or control group; N, total no. of patients in treatment or control
group; ‹ , !, values extend beyond the range of the values shown.
Use of glutamine in critical illness and surgery 265
P
ro
ce
ed
in
gs
o
f
th
e
N
u
tr
it
io
n
So
ci
et
y
Participants with pancreatitis
Parenteral glutamine was associated with a significant
reduction in mortality (RR 0.36 (95% CI 0.13, 0.99);
P = 0.05; Fig. 5) and a non-significant reduction in infec-
tion (RR 0.49 (95% CI 0.20, 1.16); P = 0.10; Fig. 6) in
participants with pancreatitis.
Examination of dose effects in parenteral and enteral
glutamine-supplemented critical illness
For trials providing ‡4.2 g glutamine/kg body weight as
the total dose over time the OR for mortality was 0.66
(95% CI 0.43, 1.01; P = 0.06) and for doses <4.2 g glu-
tamine/kg body weight OR was 0.91 (95% CI 0.66, 1.27;
P = 0.59; Fig. 7). These findings suggest that higher doses
may be more effective, but there was no significant dif-
ference between the subgroups in the interaction test
(P = 0.27). However, the trials with the higher dose of
glutamine showed high heterogeneity (I2 57%).
Conclusions
Compared with a systematic review conducted 3 years
previously(43) there have been some changes to the results
for the outcomes. The effect of glutamine on mortality is
very similar to that reported previously, with an RR of 0.71
(95% CI 0.49, 1.03) for parenteral glutamine. Although
this result is not significant, the confidence intervals do not
exclude the possibility of benefit on mortality.
The data now appear to suggest that parenteral gluta-
mine reduces infections in critical illness, but the evidence
for enteral glutamine in critical illness is less strong.
This finding is the reverse of the results from the previous
review. The possibility of publication bias for this
outcome remains a concern. The methodological quality of
nutrition-support trials in critical illness, particularly in
relation to intention-to-treat analysis, concealment of allo-
cation and blinding of outcome assessment, also requires
improvement(44).
High-dose glutamine
Conejero et al.(13)
Estivariz et al.(16)
Fuentes-Orozco et al.(17)
Garrel et al.(19)
Goeters et al.(20)
Houdijk et al.(23)
McQuiggan et al.(29)
Schulman et al.(39)
Subtotal (95 % CI)
   Total events: 44 (treatment), 60 (control)
   Test for heterogeneity: χ2 16·1, df 7 (P=0·02), I2  56·6 %
   Test for overall effect: Z 1·90 (P=0·06)
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Wischmeyer et al.(42)
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   Total events: 99 (treatment), 97 (control)
   Test for heterogeneity: χ2 11·1, df 10 (P=0·35), I2  10·0 %
   Test for overall effect: Z 0·54 (P=0·59)
Total (95 % CI)
   Total events: 143 (treatment), 157 (control)
   Test for heterogeneity: χ2 28·1, df 18 (P=0·06), I2  35·9 %
   Test for overall effect: Z 1·60 (P=0·11)
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Fig. 7. Meta-analysis of glutamine-supplemented parenteral or enteral nutrition in critical illness and surgery with OR for mortality
for the high-dose (‡ 4.2 g/kg body weight) and lower-dose (<4.2 g/kg body weight) glutamine. n, No. of patients affected in
treatment or control group; N, total no. of patients in treatment or control group; ‹ , !, values extend beyond the range of the
values shown.
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Categorisation into critical illness or surgical trials was
difficult. Trials in which participants had pancreatitis or
surgery followed by complications, e.g. peritonitis, were
classified as critical illness. All the other surgical trials of
parenteral glutamine gave parenteral nutrition after un-
complicated elective surgery, when it would not generally
have been provided. Given that parenteral nutrition itself
may be associated with an increased risk of infection, it is
not clear how the reduction of infection with parenteral
glutamine in this surgical group of patients can be inter-
preted.
Large multicentre randomised trials, with rigorous
methodology, are underway to examine the role of gluta-
mine in critical illness(45,46). The REDOXS
g
trial is
recruiting 1200 patients in North America and Europe with
organ dysfunction in critical illness(47). Participants are
randomised to 0.35 g glutamine/kg body weight per d
administered parenterally (independent of the need for
parenteral nutrition) and 30 g glutamine/d administered
enterally and/or parenteral and enteral antioxidants or no
supplements in a factorial design. The main outcome of the
trial is 28 d mortality; survival to 6 months and infections
are also outcomes. The relatively high doses of glutamine
and antioxidants have been established on the basis of
reduction in markers of oxidative stress and greater
preservation of glutathione without affecting organ func-
tion(46).
The Scottish Intensive care Glutamine or seleNium
Evaluative Trial is examining parenteral nutrition with
20.2 g glutamine with or without 500 mg parenteral Se/d,
also in a factorial design with isonitrogenous and iso-
energetic regimens, in 500 patients who require parenteral
feeding in intensive care(45).
There is no suggestion from the data in the present
review that parenteral or enteral glutamine is harmful and
the meta-analysis suggests that parenteral glutamine may
reduce organ failure; however, few trials reported details of
organ failure.
Three small trials suggest that glutamine may reduce
mortality in acute pancreatitis. However, only a total of
112 patients were enrolled in these trials and not all trials
had patients with severe pancreatitis(33). It is not clear
whether enteral nutrition support could have been achieved
in these patients(48).
There is some suggestion that higher doses (equivalent
to ‡0.42 g glutamine/kg body weight for 10 d) may have
more effect on mortality.
Two recent Cochrane reviews(49,50) have also examined
the use of parenteral or enteral glutamine in children. One
review has found insufficient evidence to support the use
of parenteral or enteral glutamine in preterm infants to
prevent morbidity and mortality(49). The other review
comes to the same conclusion for parenteral and enteral
glutamine use in young infants with severe gastrointestinal
disease(50).
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